


Researchers identify hallmarks to improving pancreatic cancer therapy

April 13 2023



Initiation and progression of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) forms from the exocrine tissue of the pancreas. Acinar and ductal cells have both shown the potential to serve as cells of origin for PDAC upon acquisition of oncogenic mutations and/or loss of tumor-suppressor function. Activating mutations in the oncogene *KRAS* are found in the two most commonly observed PDAC precursor lesions: pancreatic intraepithelial neoplasia (PanINs) and cystic lesions termed intraductal papillary mucinous neoplasms (IPMNs). In addition to *KRAS* mutations, activating mutations in the gene encoding for the G-protein alpha subunit *Gαs* (*GNAS*) and loss of function of the tumor-suppressor gene RING-type E3 ubiquitin ligase (*RNF43*) are associated with IPMNs. As these precursor lesions progress from low grade to high grade lesions, loss of the tumor-suppressor *CDKN2A* or components of the SWI/SNF chromatin-remodeling complexes are observed. Further deletion or inactivating mutations of tumor-suppressor genes *SMAD4* or *TP53* accompany the advancement of precursor lesions to PDAC. PDAC has also been classified into several RNA-based transcriptomic subtypes. Classic and basal-like have

emerged as two consensus groups, with a third “hybrid” capturing those with overlapping features. Credit: *Cell* (2023). DOI: 10.1016/j.cell.2023.02.014

Scientists from the University of California, Irvine, the University of Michigan and the University of Texas MD Anderson Cancer Center have made a significant contribution to the field of pancreatic cancer research. Their new study presents several crucial themes in the biology of pancreatic cancer that can serve as hallmarks for pancreatic cancer therapy. These themes include genomic alterations, metabolism, the tumor microenvironment, immunotherapy and innovative clinical trial design. The study appears in the journal *Cell*.

Pancreatic ductal [adenocarcinoma](#), which represents the vast majority of pancreatic cancers, is one of the most challenging and fatal forms of [cancer](#). Despite the substantial progress made in understanding the biology of PDAC over the past few decades, clinical care for most patients has not seen a major breakthrough. However, the authors believe that combined progress in these areas they have defined as hallmarks will prove transformative to the treatment of this disease.

According to Christopher Halbrook, assistant professor of molecular biology & biochemistry at UCI and lead author, "Initial efforts to target PDAC vastly oversimplified the complexity of the disease. It has taken several decades of hard work during which we have been aided by technological breakthroughs in techniques to understand intricacies of pancreatic tumors to finally provide us with a roadmap for the development of better treatments for our patients."

The authors emphasize the importance of approaching the disease from multiple angles, encompassing as many of the hallmarks as possible for the highest chance of success.

Their review summarizes the consensus models that have emerged underpinning the genetic development and path-wise progression of pancreatic tumorigenesis. It further highlights several exciting examples of ongoing research, including the development of investigational compounds and clinically deployed approaches to target the genetic and immunological features of PDAC, cancer metabolism and chemoresistance.

The authors also discuss how advances in single-cell analysis and high-dimensional spatial profiling techniques have revealed the diversity of cell populations dynamically interacting within pancreatic tumors and discuss how to begin disrupting these networks to improve response to treatment. These approaches will pair with exciting avenues of new therapeutic development, such as cancer vaccines and [antibody-drug conjugates](#), which hold enormous potential for the future of pancreatic cancer therapy.

The authors also express their optimism about the future of pancreatic cancer research and treatment.

"The previous 10 years has already seen the 5-year survival rate of PDAC double after remaining stagnant for decades prior. We are confident that the collective efforts of the scientific community will continue this trend to transform PDAC from a recalcitrant disease to a manageable disease," said Halbrook.

The authors hope that their findings will inspire further research and ultimately lead to improved treatments and outcomes for [pancreatic cancer](#) patients.

The work involved collaboration with Costas Lyssiotis and Marina Pasca di Magliano from the University of Michigan, and Anirban Maitra from the University of Texas MD Anderson Cancer Center.

More information: Christopher J. Halbrook et al, Pancreatic cancer: Advances and challenges, *Cell* (2023). [DOI: 10.1016/j.cell.2023.02.014](https://doi.org/10.1016/j.cell.2023.02.014)

Provided by University of California, Irvine

Citation: Researchers identify hallmarks to improving pancreatic cancer therapy (2023, April 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-04-hallmarks-pancreatic-cancer-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.